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Abstract
Soluble amyloid-b (Ab) aggregates of various sizes, ranging from dimers to large protofibrils, have been associated with
neurotoxicity and synaptic dysfunction in Alzheimer’s Disease (AD). To investigate the properties of biologically relevant Ab
species, brain extracts from amyloid b protein precursor (AbPP) transgenic mice and AD patients as well as synthetic Ab
preparations were separated by size under native conditions with density gradient ultracentrifugation. The fractionated
samples were then analyzed with atomic force microscopy (AFM), ELISA, and MTT cell viability assay. Based on AFM
appearance and immunoreactivity to our protofibril selective antibody mAb158, synthetic Ab42 was divided in four fractions,
with large aggregates in fraction 1 and the smallest species in fraction 4. Synthetic Ab aggregates from fractions 2 and 3
provedtobemosttoxicinanMTTassay.InAbPPtransgenicmousebrain,themostabundantsolubleAbspecieswerefoundin
fraction 2 and consisted mainly of Ab40. Also in AD brains, Ab was mainly found in fraction 2 but primarily as Ab42. All
biologically derived Ab from fraction 2 was immunologically discriminated from smaller species with mAb158. Thus, the
predominant species of biologically derived soluble Ab, natively separatedby density gradient ultracentrifugation, were found
to match the size of the neurotoxic, 80–500 kDa synthetic Ab protofibrils and were equally detected with mAb158.
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Introduction
Soluble aggregates of the amyloid-b (Ab) peptide have become the
focus of Alzheimer’s disease (AD) research as they are neurotoxic and
inhibit synapse function [1,2,3,4,5,6,7,8]. While CSF levels of Ab42
declines during the presymptomatic stages of AD [9], elevated levels of
soluble Ab in the brain has been demonstrated to correlate with AD
progression [10,11,12] and to predict synaptic degeneration [13]. In
addition, an increase in soluble brain Abprecedes plaque formation in
Down syndrome brain [14]. Several different oligomeric Ab species
have been identified both in vitro and in vivo and the Ab species
responsible for neurodegeneration and synapse dysfunction has been
suggested to be everything from Ab dimers up to large protofibrils
[15,16,17,18,19,20,21,22,23,24,25,26,27]. The potential importance
of these Ab species as targets for immunotherapy and biomarker
assays emphasizes the need to study them in closer detail in vivo.
In this study the aim was to characterize the soluble pool of
synthetic Ab as well as Ab derived from different biological samples
under conditions as native as possible. Density gradient ultracen-
trifugation [28], unlike SDS-PAGE, size exclusion chromatography
and ultra filtration, is a method where molecules are separated
based on their size in a non solid matrix without any detergents or
other denaturing agents. This approach is more likely to keep the
Ab aggregates intact during the analyses. ELISA quantification of
different Ab speciesinourcentrifuged samples followed bystructure
analysis with atomic force microscopy (AFM) allowed us to divide
the samples into four distinct fractions containing Ab of different
size and appearance. From these analyses we could conclude that
large Ab aggregates are the major Ab species in soluble extracts
from AbPP transgenic and AD patient brains.
Results
Characterization of fractionated synthetic Ab
Two different preparations of synthetic Ab were centrifuged in
an optiprep density gradient and collected in four fractions (Fig. 1).
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obtain a wide range of soluble Ab aggregates of different sizes in
contrast to freshly dissolved synthetic Ab1–40, which was used to
represent monomeric and low-molecular weight Ab species. These
Ab preparations were used to analyze how soluble Ab in different
aggregation states separated in the optiprep gradient. Most of the
freshly dissolved Ab1–40 was found in fractions 3 and 4,
containing the smallest molecules (Fig. 2A), confirming that the
Ab1–40 preparation consists of monomers and smaller oligomers.
Ab protofibril ELISA analysis of the fractionated freshly dissolved
Ab1–40 revealed tiny amounts of Ab aggregates in fraction 2 but
nothing in fraction 3 and 4, suggesting that aggregates present in
fraction 3 are too small to be detected by the conformation
dependent mAb158 of the protofibril specific ELISA. As seen in
figure 2B, all four fractions of Ab1–42 contained Ab, most of
which was found in fraction 2. Most Ab found in the two larger
fractions was detected by the Ab protofibril specific ELISA,
whereas the molecules in fraction 3 and 4 also in the Ab42
preparation were too small to be detected by the protofibril
specific ELISA. Freezing of samples prior to analysis did not affect
the results (data not shown).
Different fractions’ influence on cell viability
After adjusting each fraction to an optiprep density of 1.5% and
an Ab concentration of 0.1 mM, the four fractions of synthetic
Ab1–42 were analyzed with an MTT assay to test the fractions’
influence on PC12 cell viability. Interestingly, the two middle
fractions, containing mAb158 positive aggregates (fraction 2) and
smaller mAb158 negative oligomers (fraction 3), showed a
significantly higher toxicity than the other two fractions (Fig. 2C).
Atomic force microscopy
To get an idea of the appearance of the fractionated Ab, the
four fractions of synthetic Ab1–42 were analyzed with AFM. This
analysis revealed the largest aggregates in fraction 1 with a height
of 6 nm and a diameter of approximately 50 nm (Fig. 2D). The
aggregates were then gradually smaller, both in height and
diameter, in fraction 2 to 4 (Fig. 2E–G). Estimated molecular
weights, Mw, of the aggregates in the different fractions were
calculated with equation 1 [29] (Table 1), based on the dimensions
obtained from AFM analyses.
MW~r h=6 ðÞ 3r2zh2 
NA ð1Þ
In this equation, r is the protein density [30], h is the height and r
is the radius of the visualized structure, measured at half the
height, to compensate for tip broadening effects [29]. NA is
Avogadro’s constant.
The smallest structures, with an estimated size corresponding to
Ab monomers-tetramers, were to some extent visible in all
fractions, possibly due to diffusion of small molecules over the
gradient, caused by the high Ab concentration in the sample. For
reference, a non centrifuged sample of the Ab1–42 preparation,
aggregated for 30 min at 37uC, is displayed in Figure 2H,
containing all types of Ab species present in the fractionated
samples. Examples of these structures are marked with arrows and
numbers referring to the fraction in question. As a reference for
size, AbPP (approx. 100 kDa) and IgG (150 kDa) both ended up
in fraction 2 (data not shown).
Fractionation of AbPPArcSwe transgenic mouse brains
After verifying that the optiprep gradient is able to separate Ab
aggregates according to their size, we continued to study how a
biologically derived soluble Ab pool was separated in the same
gradient. Homogenized brains from 10 month old AbPPArcSwe
transgenic mice, at this age displaying robust Ab plaque pathology
[31], and non-transgenic mice were centrifuged and fractionated
in the same way as synthetic Ab.A b1–42 and Ab1–40 ELISA
analyses revealed that the soluble Ab pool of transgenic mouse
brain was primarily found to consist of larger aggregates ending up
in fraction 2 and to some extent in fraction 3 with an Ab42:40
ratio of approximately 1:8 (Fig. 3A–B). No Ab was detected in the
non-transgenic mice (Fig. 3). The Ab in fraction 2 of the mouse
brain homogenate was readily detectable with the Ab protofibril
specific ELISA, whereas no Ab protofibrils were detected in
fraction 3 (Fig. 3C). To further analyze the composition of the
large Ab aggregates, immunoprecipitation was performed with the
conformation dependent Ab protofibril selective antibody
mAb158 [20], covalently bound to superparamagnetic Dyna-
beads. The immunoprecipitate was then analyzed with highly
sensitive Ab1–40 and Ab1–42 ELISAs. As seen in figure 3D,
immunoprecipitated material from a pool of fraction 2 from five
mouse brain homogenates primarily contained Ab40, though with
a lower Ab40:Ab42 ratio than the starting material. Still, this result
confirms that aggregates in fraction 2 of transgenic mouse brain
were mainly composed of Ab40. No Ab was immunoprecipitated
from fraction 3 (data not shown), which is in agreement with the
Ab protofibril ELISA analysis and implies that small oligomers
have a different conformation than the larger protofibrillar Ab
species and that mAb158 only detects the larger aggregates.
Fractionation of human brains
To study the soluble Ab pool in human brain, post-mortem
temporal cortex tissue was taken from eleven individuals. Seven of
these were post mortem confirmed AD, two of which were carriers
of the Swedish or the Arctic mutation, respectively. In addition,
Figure 1. Density gradient ultracentrifugation. Schematic picture of the density gradient ultracentrifugation setup and the fractionation into
four fractions, with the largest structures in the first fraction and the smallest structures in the fourth fraction.
doi:10.1371/journal.pone.0032014.g001
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healthy control were included (table 2). Patients were diagnosed
according to the NINCDS-ADRDA criteria [32]. Samples were
homogenized, separated on the density gradient and fractioned as
above. For the analyses, the FTD brains were included in the
control group, since they were free of Ab pathology. Accordingly,
the levels of soluble Ab40 and Ab42 in non-AD brains were close
to zero (Fig. 4A–D). All AD cases had high levels of Abx-42,
especially in fraction 2, indicating a high content of large Ab
aggregates (Fig. 4A). Also Abx-40 levels were elevated in fraction 2
of some AD cases, especially in the brain homogenate from the
Swedish mutation carrier, but there was a large variability
(Fig. 4B). In line with earlier observations [33], detection with
the N-terminal 82E1 antibody revealed substantially lower levels
of the full length Ab1–42 and Ab1–40 (Fig. 4C–D), caused by a
substantial degree of N-terminal truncation of soluble Ab in AD
brain, with an average of 90% truncated Ab42 in AD brain and
around 15% in non-AD brain (Fig. 4E).
Thus, although high levels of Ab42 were found in fraction 2 of
the AD brains, no reliable Ab protofibril ELISA analysis could be
carried out. Since the Ab protofibril ELISA is dependent on at
least two epitopes with intact Ab N-termini to generate a signal,
this truncation lead to a considerable underestimation of
protofibril levels. Instead, the Ab aggregates in pooled material
from fraction 2 of AD and non-AD brain were analyzed with
mAb158 immunoprecipitation, requiring fewer intact N-terminal
epitopes, followed by ultra sensitive Ab1–40 and Ab1–42 ELISA
analysis. As displayed in figure 4F, the starting material contained
around 40% Ab1–40 and 60% Ab1–42, whereas the immuno-
precipitate contained 95% Ab1–42. This was also reflected in the
supernatant, where the Ab42 level had dropped significantly,
whereas Ab40 remained more or less the same. When performing
the same analysis on fraction 3 of AD and non-AD brain, no Ab
was immunoprecipitated (data not shown).
Discussion
Many different oligomeric Ab species have been described in
the literature, but there is no consensus about which species
actually exist and exert neurotoxic activity in the human brain.
Small, naturally derived Ab oligomers have been suggested to
potently cause synaptic failure [26] and neuritic degeneration [34],
possibly via aggregation into large protofibrils [35], and large Ab
aggregates in brain extracts and CSF have recently been
associated with AD [27,36]. Immunotherapy with antibodies able
to neutralize the toxicity of oligomeric Ab species have been
Figure 2. Fractionation of synthetic Ab1–40 and Ab1–42. Each of the four fractions of the Ab40 and Ab42 preparations was analyzed with
ELISA for total levels of Ab1–40 and Ab1–42 respectively as well as for protofibril levels (A–B). Graphs show mean of three different fractionated Ab
preparations and error bars indicate the standard deviation. Equal amounts of Ab (0.1 mM) from the Ab1–42 fractions were also analyzed with MTT
cell viability assay with PC12 cells (C). The MTT graph shows the mean of three analyses of three different fractionated Ab1–42 preparations. The
analyses are standardized with an internal Ab control and all fractions were diluted to a final Ab concentration of 0.1 mM and an optiprep
concentration of 1.5% prior to addition to the cells. Error bars indicate the standard deviation. Ab1–42 fractions were also analyzed with AFM (D–G).
Scale bar=100 nm. Curves under AFM images represent the topography of the area marked by a line in each image. An AFM image of a non
centrifuged preparation of Ab1–42 is shown for reference (H). Arrows point at structures resembling those present in the four different fractions of
centrifuged Ab1–42.
doi:10.1371/journal.pone.0032014.g002
Table 1. Molecular sizes of fractionated synthetic Ab42,
determined with AFM.
Fraction Diameter (nm) Height (nm)
Mw
(kDa) Ab n
1 25–50 2.9–7.5 200–2000 44–440
2 25–40 1.8–3.0 80–500 18–114
3 15–25 0.8–1.2 20–80 4–18
4 12–15 0.3–0.8 5–20 1–4
doi:10.1371/journal.pone.0032014.t001
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is important to characterize the soluble Ab pool of i.e. brain
extracts from AD patients.
Here, density gradient ultracentrifugation was used to investi-
gate the size distribution and structure of soluble Ab from
synthetic preparations and to compare them to different biological
samples. This is a native and gentle method, which is important in
order to maintain the structure of the Ab aggregates. Based on
observations of centrifuged synthetic Ab, we could divide our
samples into four distinct fractions, all containing Ab species of
different size and with different appearances in AFM. We have
previously reported that Ab protofibrils, recognized by our
conformation dependent antibody mAb158, have an elongated
structure when visualized by cryo-TEM [20]. Such protofibrils end
up in fraction 2 when centrifuged on the same gradient as
presented here (data not shown). Thus, the rounded shape of the
larger aggregates seen in figure 2 was, although reported by others
[41], somewhat unexpected. This could, to a certain degree, be an
artifact caused by the attachment of samples to the mica surface, as
this was not done in solution. Synthetic Ab aggregates found in
fraction 1 and 2 were mAb158 positive, whereas Ab from fraction
3 and 4 were not, implying that the Ab aggregates are
conformationally different. In agreement with previous observa-
tions using the same method [28], we found that synthetic Ab
aggregates of intermediate size, found in fraction 2 and 3, exerted
the highest toxicity to PC12 cells. Hence, the synthetic Ab
preparation appears to contain two pools of neurotoxic Ab
aggregates: a mAb158 positive pool of slightly larger aggregates
and a mAb158 negative pool of smaller oligomers.
The different preparation of mouse and human brain tissue
before density gradient centrifugation could potentially result in
different relative amounts of Ab being present in these samples.
Despite that, there was a striking resemblance between the
biologically derived Ab, originating from AbPPArcSwe transgenic
mouse brain and from AD brain, with respect to size distribution
and structure. Most Ab from these samples was found in fraction 2
and had an estimated size of 80–500 kDa. Ab from fraction 2 of
the biological samples was recognized by mAb158, implying a
common structure that can be immunologically discriminated
from smaller oligomers, as shown by others [42,43,44]. Since
mAb158 does not discriminate between Ab40 and Ab42
aggregates in vitro [45,46], this structure seems to be independent
of which Ab peptide is the main constituent of the aggregates. As
previously reported, Ab40 was the predominant Ab peptide in
AbPPArcSwe transgenic mouse brain [47] and this peptide was
abundantly detected as mAb158 positive aggregates in fraction 2.
The large amount of Ab40 incorporated in aggregates may be a
result of the massive overproduction of Ab in general, caused by
Figure 3. Fractionation of transgenic mouse brain extracts. Fractions of mouse brain homogenate from AbPPArcSwe transgenic mice (n=5)
and non-transgenic littermates (n=5) were analyzed with Ab1–42 (A), Ab1–40 (B) and Ab protofibril specific (C) ELISAs. Horizontal lines indicate the
mean value of each group. Immunoprecipitation of pooled material from fraction 2 of transgenic mouse brain homogenate with the conformation
specific Ab protofibril selective antibody mAb158 covalently coupled to Dynabeads (0 – non immunoprecipitated sample, IP – immunoprecipitated
material, S – supernatant remaining after ip) (D). Error bars indicate the standard deviation.
doi:10.1371/journal.pone.0032014.g003
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enhancing Arctic mutation. AD brains, on the other hand,
contained mostly Ab42 as described earlier [12] although a subset
of them, notably the Swedish mutation carrier, had high levels of
Ab40, similar to the transgenic mice. Interestingly, Ab aggregates,
immunoprecipitated with mAb158 from fraction 2 of pooled AD
brain material, contained almost exclusively Ab42 despite a
considerable amount of Ab40 in the starting material. This result
suggests that while Ab42 in the AD brain is incorporated in large
mAb158 positive aggregates, Ab40 may have ended up in fraction
2 as monomers or small, mAb158 negative aggregates, possibly in
complex with other large molecules.
Although synthetic and biologically derived Ab may not be
directly comparable, mainly because of differences in sample
matrices, it is intriguing that most Ab found in our biological
samples ends up in fraction 2, where some of the most toxic
synthetic Ab species are found. This observation is in line with
previous reports about size and function of Ab aggregates, both
synthetic [35,41,46] and from human brain tissue [27,48].
In conclusion, although different in Ab peptide composition and
amount of N-terminal truncation, soluble Ab aggregates from
AbPPArcSwe transgenic mouse brain and AD brain, mainly found
in fraction 2, appear to be similar in both structure and size, as
indicated by their binding to the protofibril selective, conformation
dependent antibody. Furthermore, biologically derived soluble Ab
aggregates resemble the neurotoxic aggregates found in fraction 2
of a synthetic Ab preparation. These insights may be of relevance
for the further development of immunotherapy directed against
soluble species of aggregated Ab.
Materials and Methods
Ethics statement
The use of human and mouse brain material was approved by
the Regional ethical committee in Uppsala (decision numbers
C223/8 and 2005–103). Written informed consent was obtained
from all subjects (or their relatives) involved in the study.
Density gradient ultracentrifugation
A density gradient, for fractionation of samples by ultracentri-
fugation, was obtained using optiprep (Sigma-Aldrich, Stockholm,
Sweden) diluted in phosphate buffered saline (PBS). The gradient
was prepared by layering 0.65 ml of 50% optiprep at the bottom
of a 4.9 ml OptiSeal
TM Polyallomer centrifuge tube (Beckman
Coulter, Bromma, Sweden) followed by 0.65 ml of 40%, 1.95 ml
of 30%, 0.65 ml of 20% and 0.65 ml of 10% to give a final
discontinuous gradient of 4.55 ml. A 0.25 ml aliquot of sample
was carefully loaded onto the top of the gradient before
centrifugation. An NVT65.2 rotor (Beckman Coulter) was used,
and synthetic as well as biological samples were centrifuged at
384 0006g for 3 h at +4uC. Fractions (1–1.65 ml, 2–0.9 ml, 3–
0.9 ml, 4–1.35 ml), were collected from the bottom of the tube,
aliquoted and stored at 220uC until analysis.
Synthetic Ab samples
Synthetic Ab1–42 (American Peptide Company Inc., Sunnyvale,
CA, USA), dissolved in 10 mM NaOH, diluted in 106 PBS to
443 mM (2 mg/ml), was incubated for 30 min at 37uCa n d
centrifuged for 5 min at 17 9006g to remove any insoluble
aggregates. It was then immediately applied to the density gradient
for ultracentrifugation (The high concentration [443 mM] was
required to perform the toxicity studies, where all fractions were
diluted to the same final Ab concentration.). Synthetic Ab1–40
(AmericanPeptide Company Inc.), dissolvedin10 mMNaOH,was
diluted in 26PBS to 50 mM immediately prior to centrifugation.
Human and mouse brain homogenates
Saline perfused brain hemispheres, with a weight of approximately
150 mg, from AbPPArcSwe transgenic mice [31] (n=5) and non-
transgenic littermates (n=5) were homogenized using a tissue grinder
with teflon pestle (2610 strokes on ice) in tris buffered saline (TBS)
(20 mM tris, 137 mM NaCl, pH 7.6 and Complete protease inhibitor
cocktail (Roche, Bromma, Sweden)) in a 1:10 (tissue weight:extraction
volume) ratio. Homogenates were centrifuged at 100 0006g at 4uCf o r
1 h to obtain a preparation of TBS-soluble extracellular and cytosolic
proteins. Supernatants were aliquoted and stored at 280uCu n t i l
analysis. Human brain samples of approximately 500 mg, obtained
from temporal cortex, were homogenized 1:5 (tissue weight:extraction
volume) in TBS (as above) and clear homogenate supernatants were
obtained by centrifugation at 16 0006g for 1 h at 4uC.
Ab40 and Ab42 ELISA
96-well plates were coated with polyclonal antibodies specific for
the C-terminal 40 or 42 Ab neo-epitopes respectively [12] and
blocked with 1% BSA in PBS. Samples were denatured by boiling
5 min in 0.5% sodium dodecyl sulphate (SDS) to avoid impaired
Ab quantification due to presence of aggregates [49]. After
dilution 1:5 in ELISA incubation buffer (PBS, 0.1% BSA, 0.05%
Tween) samples were added to the ELISA plates and incubated for
2 h. A one hour incubation with biotinylated 4G8 (Nordic Biosite,
Ta ¨by, Sweden), a monoclonal antibody binding to amino acid
residue 18–22 within the Ab sequence, or 82E1 (IBL, Hamburg,
Germany), specific for the N-terminal Ab neo-epitope (Ab amino
acid residue 1–5), generated by BACE cleavage of AbPP, followed
by streptavidin-HRP (Mabtech AB, Nacka Strand, Sweden), and
tetramethyl-benzidine (TMB) (ANL produkter, A ¨lvsjo ¨, Sweden)
were used for detection and the optical density was measured at
450 nm. Alternatively, samples were treated as above but analyzed
with Ab1–40 ELISA kit Wako II or Ab1–42 ELISA kit Wako, High
sensitivity (Wako Chemicals GmbH, Neuss, Germany) according to
the manufacturer’s instructions. The optiprep matrix or the SDS
(0.1%) did not disturb ELISA quantifications (data not shown).
Ab protofibril specific ELISA
The protofibril specific sandwich ELISA, based on mAb158
both as capturing and detecting antibody and thus excluding the
Table 2. Summary of cases.
Case
Neuropath.
diagnosis Age at onset Age at death
Disease
duration
001 AD (Swe) 58 61 3
004 F T D 6 17 09
005 F T D 5 26 19
006 AD 80 92 12
008 F T D 6 26 64
009 AD (Arc) 56 64 8
010 AD 83 85 2
011 AD n.d. 76 n.d.
012 ctrl n.a. 88 n.a.
013 AD 71 77 6
021 AD 53 63 10
doi:10.1371/journal.pone.0032014.t002
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Englund et al. [20]. In short, 96-well plates were coated with
mAb158 and blocked with 1% BSA in PBS. Synthetic Ab and
mouse brain samples were diluted in ELISA incubation buffer
(PBS, 0.1% BSA, 0.05% Tween), whereas human samples were
diluted in ELISA plasma diluent (Mabtech AB) to avoid
interference from heterophilic antibodies [50]. Samples were
incubated for 2 h at room temperature (RT) before addition of
biotinylated mAb158. Streptavidin coupled HRP (Mabtech AB)
and TMB (ANL produkter) were used for detection and the optical
density was measured at 450 nm.
MTT cell toxicity assay
PC12 cells [51] (obtained from A–L Svensson, Uppsala
university [52]) were plated at a density of 10 000 cells/well in a
96 well plate (cell+, Sarstedts, Sweden) and incubated for 18 h at
Figure 4. Fractionation of human brain extracts. Fractions of human brain homogenate from temporal cortex of diseased AD patients (n=7,
including one AbPPSwe and one AbPPArc mutation carrier) and non-AD subjects (n=4, one control subject and three FTD patients) were analyzed with
Abx-42 (A), Abx-40 (B), Ab1–42 (C) and Ab1–40 (D) ELISAs. Results from the individual carrying the Swedish mutation is marked ‘Swe’ in the Abx-40
and Ab1–40 graphs. Horizontal lines indicate the mean value of each group. The level of N-terminal truncation of Ab42 was determined as a ratio
between Ab1–42 and Abx-42 (1-[Ab1–42]/[Abx-42]) (E), with error bars indicating the standard deviation. Immunoprecipitation of pooled material
from fraction 2 of AD brain and non-AD brain with the conformation specific Ab protofibril selective antibody mAb158 covalently coupled to
Dynabeads (0 – non immonuprecipitated sample, IP – immunoprecipitated material, S – supernatant remaining after ip) (F). Error bars indicate the
standard deviation.
doi:10.1371/journal.pone.0032014.g004
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supplemented with 10% dialyzed FBS (fetal bovine serum,
Invitrogen). Ab concentration in the different fractions was
determined by Ab42 ELISA after SDS-denaturation (see above).
New aliquots of the synthetic Ab42 fractions were thawed and
added to the wells immediately after dilution to a final Ab
concentration of 0.1 mM and an optiprep concentration of 1.5%.
A set of optiprep samples (1.5%) without Ab was used as control
and subtracted from the Ab toxicity. PBS and 0.005% H2O2 were
used as negative and positive controls respectively. Plates were
incubated with samples and controls for 4 h at 37uC followed by
addition of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) at a final concentration of 0.5 mg/ml. Solubili-
zation of the formazan product was achieved by addition of
100 ml/well of solubilization buffer (20% SDS in dimethyl-
formamide, pH 4.8) followed by 24 h of incubation at 37uC.
The formazan product was quantified by absorbance measure-
ment at 570 nm. Three independent experiments were performed
and standardized with an internal Ab control (Ab42, incubated
30 min at 37uC and centrifuged 5 min at 17 9006g).
Atomic Force Microscopy
AFM analyses were carried out with an XE-150 large sample
AFM system (Park Systems Corp., Santa Clara, CA, USA)
equipped with a 150 mm6150 mm XY scanner. All measure-
ments were performed at ambient temperature in true non-contact
mode using silicon based AFM probes (ACTA, AppNano, Santa
Clara, CA). Fractions of ultracentrifuged synthetic Ab42 were
diluted in PBS to a final concentration of 250 nM. A 10 ml aliquot
of each sample was adsorbed to a freshly cleaved mica surface
(Veeco, Cambridge, UK) over night at RT and then washed with
distilled water and air dried. All analyses were performed with a
scan rate of 1 Hz, with a set point between 0.93 and 1.79 mm and
a Z servo gain between 1.07 and 1.83. Images were flattened and
Sobel processed with XEI image analysis program (Park Systems
Corp.). Sizes of the visualized structures were estimated using
Equation 1, as explained in the results section.
mAb158 immunoprecipitation
The monoclonal Ab protofibril selective antibody mAb158
[20,45] was covalently attached to superparamagnetic beads with
the Dynabeads coupling kit (Invitrogen). mAb158-coupled beads
(5 ml) were added to pooled material of fraction 2 from AD brain
(n=7), non-AD brain (n=4) or AbPPArcSwe transgenic mouse
brain (n=3) in the presence of 0.05% Tween 20 and incubated
1 h on a shaker. After three washes in PBS with 0.05% Tween 20,
beads as well as supernatant and the starting material were boiled
5 min in 0.5% SDS. The beads were removed with a magnet and
samples were diluted 5 times in standard diluent and analyzed
with Ab1–40 ELISA kit Wako II or Ab1–42 ELISA kit Wako, High
sensitivity (Wako Chemicals GmbH) according to the manufactur-
er’s instructions.
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